Write a PK report using other human biomaterials

When does a human-biomaterial report belong in CTD 5.3.2.3?

Use this family for appropriate PK studies with human biomaterials that do not fit the more specific protein-binding or hepatic-metabolism categories. Establish the experiment’s purpose and actual system first. Human material alone does not make a non-PK experiment a Module 5 study or establish clinical relevance.

Before you begin

PK-oriented in-vitro or ex-vivo reports using human biomaterials outside the protein-binding and hepatic-metabolism categories.

What you will prepare: A clearly classified experimental report with material identity, controls, reproducible results and limited translational claims.

Use the biological question to classify the report

The phrase “human cells” describes the material, not the submission location. First establish whether the experiment assesses a PK property, such as permeability or transport, rather than a pharmacodynamic effect or product-quality characteristic. M4E uses 5.3.2.3 for other human-biomaterial PK studies; its neighboring headings cover protein binding and hepatic metabolism.

Obtain the experimental objective, material origin, protocol and final laboratory report before choosing the destination. A recombinant or mixed-species system needs its actual design and purpose examined; do not classify it as human merely because a human target appears in the title. Unclear provenance stays an open placement question for the regulatory and scientific owners.

Make the model system understandable

For a transport or permeability experiment, describe the model's origin, preparation, relevant expression or functional characteristics and the conditions under which it was tested. Identify the test article, concentrations, direction or compartment of measurement, analytical method, controls and calculations. Explain how the experiment distinguishes the process of interest from passive movement, nonspecific loss or system failure where those issues matter.

Present observed results and uncertainty before discussing human relevance. Separate a measured property of the model from a predicted clinical exposure effect. For an interaction assessment, apply the relevant mechanism-specific M12 considerations and identify the evidence still needed for translation; the report is not a universal clinical interaction screen.

Check the direction and denominator of the result

Fictional exercise: two tables report a transport ratio, but one uses the reverse numerator and denominator. Both are copied into the pharmacology summary as if directly comparable. Trace the definitions and source calculations, correct the inconsistent label or transformation through the scientist, and check every downstream use.

Before closing the report, reconcile units, compartment names, concentration basis and material identifiers. If the control does not establish that the model functioned for the tested mechanism, state the limitation and request the missing assessment. A polished graph cannot replace evidence that the experimental system answered the intended question.

Define direction, compartment and denominator before combining results

Use a measurement dictionary when results from different laboratories or systems appear in one report.

Reconciliation exercise: two laboratories report the same named ratio but define its direction differently. Preserve both source definitions, obtain the scientist's agreed comparison and check any transformed outputs. Renaming the column alone is not a mathematical correction.

Use the hepatic metabolism guide when that more specific family fits. Transfer the final definitions into the clinical pharmacology summary so a shorter account does not reverse the meaning of the original experiment.

Frequently asked questions

Sources and revisions

Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.

Related guides